Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 2/2013

01-04-2013 | Urothelial Cancer (A Sagalowsky, Section Editor)

Current Role of PET, CT, MR for Invasive Bladder Cancer

Authors: Nathan Lawrentschuk, Sze Ting Lee, Andrew M. Scott

Published in: Current Urology Reports | Issue 2/2013

Login to get access

Abstract

Imaging for urothelial cancer, particularly that located in the bladder, has generally been based on computed tomography (CT). However in more recent times the role of positron emission tomography-CT (PET-CT) has emerged and increasingly magnetic resonance (MR) imaging has become utilised. This concise review will outline the role of these modalities when dealing with muscle-invasive bladder cancer (MIBC).
Literature
1.
2.
3.
•• Lee ST, Lawrentschuk N, Scott AM. Pet in prostate and bladder tumors. Semin Nucl Med. 2012;42:231–46. A comprehensive analysis on the limitations of staging as it currently stands for muscle invasive bladder cancer including with contemporary imaging.PubMed
4.
Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS. The updated eau guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2009;55:815–25.PubMedCrossRef
5.
National Comprehensive Cancer Network (NCCN). Nccn clinical practice guidelines in oncology (nccn guidelines®)-bladder cancer 2012 (Version 1, 2013).
6.
Bostrom PJ, van Rhijn BWG, Fleshner N, Finelli A, Jewett MA, Thoms J, et al. Staging and staging errors in bladder cancer. Eur Urol Suppl. 2010;9:2–9.CrossRef
7.
• Vargas HA, Akin O, Schoder H, Olgac S, Dalbagni G, Hricak H, et al. Prospective evaluation of mri, (11)c-acetate pet/ct and contrast-enhanced ct for staging of bladder cancer. Eur J Radiol. 2012;81:4131–7. One of the few prospective studies examining CT, PET-CT and MR in a prospective fashion to stage bladder cancer.PubMedCrossRef
8.
Purysko AS, Leao Filho HM, Herts BR. Radiologic imaging of patients with bladder cancer. Semin Oncol. 2012;39:543–58.PubMedCrossRef
9.
• Green DA, Durand M, Gumpeni N, Rink M, Cha EK, Karakiewicz PI, et al. Role of magnetic resonance imaging in bladder cancer: Current status and emerging techniques. BJU Int. 2012;110:1463–70. A comprehensive analysis of the benefits and pitfalls of MR in bladder cancer as a staging tool for bladder cancer with a call for more prospective studies.PubMedCrossRef
10.
Giannarini G, Petralia G, Thoeny HC. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. Eur Urol. 2012;61:326–40.PubMedCrossRef
11.
Lu YY, Chen JH, Liang JA, Wang HY, Lin CC, Lin WY, Kao CH. Clinical value of fdg pet or pet/ct in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol. 2011.
12.
Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol. 2000;163:1693–6.PubMedCrossRef
13.
Anjos DA, Etchebehere EC, Ramos CD, Santos AO, Albertotti C, Camargo EE. 18f-fdg pet/ct delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med. 2007;48:764–70.PubMedCrossRef
14.
Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med. 1997;24:615–20.PubMed
15.
Schoder H, Ong SC, Reuter VE, Cai S, Burnazi E, Dalbagni G, et al. Initial results with (11)c-acetate positron emission tomography/computed tomography (pet/ct) in the staging of urinary bladder cancer. Mol Imaging Biol. 2012;14:245–51.PubMedCrossRef
16.
Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. Fdg-pet for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging. 2005;32:1412–7.PubMedCrossRef
17.
Harkirat S, Anand S, Jacob M. Forced diuresis and dual-phase f-fluorodeoxyglucose-pet/ct scan for restaging of urinary bladder cancers. Indian J Radiol Imaging. 2010;20:13–9.PubMedCrossRef
18.
Kibel AS, Dehdashti F, Katz MD, Klim AP, Grubb RL, Humphrey PA, et al. Prospective study of [18f]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol. 2009;27:4314–20.PubMedCrossRef
19.
Bachor R, Kotzerke J, Reske SN, Hautmann R. Lymph node staging of bladder neck carcinoma with positron emission tomography. Urologe A. 1999;38:46–50.PubMedCrossRef
20.
Apolo AB, Riches J, Schoder H, Akin O, Trout A, Milowsky MI, et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol. 2010;28:3973–8.PubMedCrossRef
21.
Jadvar H, Quan V, Henderson RW, Conti PS. [f-18]-fluorodeoxyglucose pet and pet-ct in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol. 2008;13:42–7.PubMedCrossRef
Metadata
Title
Current Role of PET, CT, MR for Invasive Bladder Cancer
Authors
Nathan Lawrentschuk
Sze Ting Lee
Andrew M. Scott
Publication date
01-04-2013
Publisher
Current Science Inc.
Published in
Current Urology Reports / Issue 2/2013
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-013-0308-y

Other articles of this Issue 2/2013

Current Urology Reports 2/2013 Go to the issue

Bladder and Urothelial Cancer (A Sagalowsky, Section Editor)

Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer

Bladder and Urothelial Cancer (A Sagalowsky, Section Editor)

Improvements in Safety and Recovery Following Cystectomy: Reassessing the Role of Pre-Operative Bowel Preparation and Interventions to Speed Return of Post-Operative Bowel Function

Minimally Invasive Surgery (V Bird, Section Editor)

Update on use of Enhanced Imaging to Optimize Lymphadenectomy in Patients Undergoing Minimally Invasive Surgery for Urothelial Cancer of the Bladder

Minimally Invasive Surgery (V Bird, Section Editor)

Evaluation of Renal Masses with Contrast-Enhanced Ultrasound

Urothelial Cancer (A Sagalowsky, Section Editor)

Value of Fluorescence Cystoscopy in High Risk Non-muscle Invasive Bladder Cancer

Minimally Invasive Surgery (V Bird, Section Editor)

Advances in Tubeless Percutaneous Nephrolithotomy and Patient Selection: An Update